ArticleHematological oncology2025
Tissue-Equivalents of Lymphoid Clonal Hematopoiesis of Indeterminate Potential (L-CHIP) and Germline-Derived Lymphoproliferations: Possible Caveats for Hematopathologists.
Article in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is a predisposing condition to lymphoma development. CHIP carrying mutations that are recurrently found in lymphomas are designated as L-CHIP. We presume that bone marrow-derived L-CHIP populations are able to expand and manifest in peripheral lymphoid tissues, where they could hence be called L-CHIP tissue-equivalents. There, they may proliferate and foster unexplained follicular hyperplasias, and, thus, potentially represent an early precursor of lymphoma. Analogously, we hypothesize that certain germline-derived mutations lead to lymphoproliferations (germline-derived lymphoproliferations) in otherwise healthy individuals. We collected seven exceptional cases of symptomatic nodal and extranodal lymphoid hyperplasias, which were all morphologically suspicious and displayed somatic and/or germline-derived mutations recurrently found in B-cell lymphomas. One patient developed follicular lymphoma after 8 years carrying the same non-productive immunoglobulin rearrangement detected in the initial biopsy. L-CHIP tissue-equivalents and germline-derived lymphoproliferations potentially represent first steps in lymphomagenesis and knowledge about their existence might be of diagnostic utility in challenging cases of (atypical) lymphoproliferations. With histology, immunohistochemistry, and molecular testing, such lesions can be identified in situ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.